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ABSTRACT: Background: Five to 25% of patients with
PD carry glucocerebrosidase gene mutations, and 10% to
30% of glucocerebrosidase carriers will develop PD by age
80. Stratiﬁcation of PD risk in glucocerebrosidase carriers pro-
vides an opportunity to target disease-modifying therapies.
Objective: Cross-sectional and longitudinal survey of
prodromal PD signs among glucocerebrosidase carriers.
Design: Prospective assessment of 82 glucocerebrosidase
mutation carriers and 35 controls over 4 to 5 years for prodro-
mal clinical PD features.
Results: At all timepoints, olfactory (measured usingUniver-
sity of Pennsylvania Smell Identiﬁcation Test) and cognitive
(Montreal Cognitive Assessment) function and the Interna-
tional Parkinson and Movement Disorder Society UPDRS
parts II and III scores were signiﬁcantly worse amongst
glucocerebrosidase mutation carriers. Progression to micro-
smia (odds ratio: 8.5; 95% conﬁdence interval: 2.6–28.2;
P < 0.05) andmild cognitive impairment (odds ratio: 4.2; 95%
conﬁdence interval: 1.1–16.6; P < 0.05) were more rapid
compared to controls. Those with worse olfaction also had
worse cognition (OR, 1.5; 95% CI: 0.0–2.8; P < 0.05) and
depression (OR, 1.3; 95% CI: 0.6–2.8; P < 0.05). No partici-
pants reached the MDS prodromal PD diagnostic criteria
before PD diagnosis. One participant developed PD. He did
not fulﬁll the International Parkinson and Movement Disorder
Society prodromal PD criteria before diagnosis.
Conclusion: Assessment of individual and clusteredPDpro-
dromal featuresmay serve as a useful tool to identify high-risk
subjects for conversion to PD. As a result of the low conver-
sion rate in our glucocerebrosidase mutation carriers to date,
prospective validation is needed in larger cohorts to establish
the proﬁle of these features in PD convertors. © 2019 The
Authors.Movement Disorders published byWiley Periodicals,
Inc. on behalf of International Parkinson andMovementDisor-
der Society.
Key Words: cognition; depression; glucocerebrosidase;
Gaucher; olfaction; Parkinson’s; prodromal
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Mutations in the lysosomal glucocerebrosidase gene
(GBA1) are the most signiﬁcant genetic risk factor for
Parkinson disease (PD). Five to 10% of PD patients carry
aGBA1mutation, rising to 25% in high-risk groups such
as Ashkenazi Jews.1 In the biallelic (i.e., homozygous or
compound heterozygous carrier of a GBA1 mutation)
state,GBA1mutations cause the lysosomal storage disor-
der, Gaucher disease (GD).2 Biallelic and heterozygous
GBA1 mutations increase the risk for PD and dementia
with Lewy bodies,1,3 but display incomplete penetrance
for PD with 10% to 30% affected by age 80.4,5 Those
GBA1 mutations associated with the more severe neu-
ronopathic form of GD have a higher risk of developing
PD.6 The two most common mutations are N370S and
L444P. Respectively, they increase the risk of PD by ≈4-
and ≈8- to 12-fold.7 Common GBA1 variants, such as
T369Mand E326K, increase the risk by≈1.5-fold, but are
not associated with GD.7
The GBA1 metabolic pathway is an attractive target
for neuroprotective therapy in PD.8,9 Disease-modifying
treatments are likely to be most effective when given
early, for instance during a prodromal phase of micro-
smia, constipation, depression, dysautonomia, rapid eye
movement sleep behavior disorder (RBD), and cognitive
impairment. We present the third prospective assess-
ment for prodromal PD features of a cohort of GBA1
mutation carriers, 4 to 5 years after baseline.10,11 Our
ﬁndings suggest that a combination of clinical markers
may help deﬁne a subgroup of GBA1 mutation carriers
at increased risk of PD.
Materials and Methods
Participants
Type 1 GD patients aged >40 years were recruited from
the Royal Free London Hospital from 2010. These
patients are biallelic for GBA1 mutations. Heterozygous
GBA1+ relatives were recruited from their kindred. Con-
trols were unrelated. The group of heterozygous GBA1
carriers + biallelic carriers will be referred to as the com-
binedGBA1 group. All participants were free of neurolog-
ical features at inclusion.10,11 Participants were assessed
longitudinally from baseline (2010–2011), with target
assessments in 2012–2013 (time point 1) and 2014–2015
(time point 2). Previous studies referred to age-matched
populations, whereas the present analysis encompasses
these and additional cases drawn from our longitudinal
database. The study was approved by the Hampstead
Research Ethics Committee (10/H0720/21). A full list of
subjects’mutations is available in Supporting Information
Table S1.
We used a rolling recruitment model to enrol new par-
ticipants throughout the duration of the study (see
Supporting Information Fig. S2). These participants had
their ﬁrst assessment added to the baseline group
regardless of the year of assessment. At baseline, there
were 117 participants (35 controls, 39 heterozygous, and
43 biallelic), 103 at time point 1 (28 controls, 33 heterozy-
gous, and 42 biallelic), and 85 at time point 2 (19 controls,
26 heterozygous, and 40 biallelic). In a rolling recruitment
model, new participants were enrolled into the study in
2012–2013 (2 control, 1 heterozygous, and 2 biallelic)
and 2014–2015 (3 control, 3 heterozygous, and 1 biallelic)
and analyzed as baseline. Eleven control participants
dropped out of the study (4 at time point 1 and 7 at time
point 2; 31%), 3 declined to take part, 4 were lost to fol-
low up, 2 were too frail/ill to undergo assessment, and
2 died. In the heterozygous group, there were 9 dropouts
(23%; 3 at time point 1 and 6 and time point 2). Three
declined to take part, 3 were lost to follow-up, and 3 were
too frail/ill to undergo assessment. In the bi-allelic group,
there were 2 dropouts (5%) both at time point 2. Both
declined to take part. All participants lost to follow-up
were contacted by phone, e-mail and post. A ﬂow diagram
of recruitment and retention is displayed in Supporting
Information Figure S2.
Follow-up Evaluation
A standardized clinical history and neurological
assessment was conducted, including the International
Parkinson and Movement Disorder Society UPDRS
(MDS-UPDRS) parts II and III, the University of Pennsyl-
vania Smell Identiﬁcation Test (UPSIT), the Montreal
Cognitive Assessment (MoCA), the Rapid Eye Move-
ment Behaviour Disorder Sleep Questionnaire (RBDSQ),
and the Beck’s Depression Inventory (BDI). Participants
were examined independently by a physician trained in
movement disorders (A.M., M.B., or S.M.). A blinded
senior movement disorders neurologist (A.H.V.S.) evalu-
ated participants upon deterioration in MDS-UPDRS
scores.
Genotyping
Sequencing of the GBA1 gene was carried out as
described previously12 (primers available on request).
All subjects were genotyped, including controls.
Standardization of MDS-UPDRS Testing
To ensure consistency in MDS-UPDRS part III scor-
ing, investigators carried out a blinded assessment of
4 patients with a clinical diagnosis of PD and compared
scores. Across the MDS-UPDRS III section, average
score deviation was 1.75 points (range, 0–4).
Missing Data
A sensitivity analysis, in which a regression model for
respective dependent variables at each time point, was
constructed and showed data were “missing at ran-
dom.” For each variable, percentages of missing data
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(including missing data for participants who dropped
out of the study) were as follows:
Baseline Time Point 1 Time Point 2
UPSIT 7% 21% 32%
MoCA 4% 20% 33%
RBDSQ 1% 25% 35%
BDI 30% 35% 32%
MDS-UPDRS II 0% 20% 34%
MDS-UPDRS II 1% 20% 33%
We used multiple imputation using chained equations
(m = 50) to impute missing data. All study covariates
were included in the derivation of imputed values.
Clinical Data Analysis
Data were analyzed using Stata software (version
14.1; StataCorp LP, College Station, TX). Graphs were
plotted using Stata and Microsoft Excel (v.15.17;
Microsoft Corporation, Redmond, WA).
Analysis Strategy
Our primary analysis was the combined GBA1 versus
control groups. For signiﬁcant associations, we carried
out secondary analyses comparing biallelic/heterozygous
groups to controls. We also carried out a separate analysis
looking at the inﬂuence of the total number of severe
mutations across two alleles among the entire GBA1
mutation carrying cohort.
Study Covariates
We assessed the confounding effect of study covariates
and variation of group demographics with descriptive
statistics and a Kruskal-Wallis test (Table 1). Covariates
were included if there was evidence of a signiﬁcant differ-
ence in the characteristics of the participants across dif-
ferent groups at any time point (P < 0.05) and/or if there
was a strong biological rationale for their inclusion. As a
result, the following study covariates were included: sex,
education (university/nonuniversity educated), family
history of PD/dementia, number of severe GBA1 muta-
tions, signiﬁcant past smoking history (>1 pack year),
and age.
Sample Distributions
Non-normally distributed data for all dependent vari-
ables precluded parametric analyses, taking into account
covariate risk factors. Nonewere amenable to transforma-
tion, so, where possible, we chose to stratify data using
clinically validated thresholds.
Cross-Sectional Analyses
Where possible (MoCA, BDI, UPSIT, and RBDSQ),
data were categorized according to clinically validated
thresholds:
UPSIT: <19 anosmia, 20 to 24 severe microsmia, 25 to
29 microsmia, 30 to 33 mild microsmia13
MoCA: <25 dementia, 25 to 26 mild cognitive
impairment14
RBDSQ: >5 RBD15
BDI: 9 to 19 mild depression, 20 to 29 moderate
depression, >29 severe depression16
Ordinal logistic regression was used to determine
associations between the combined GBA1 cohort and
controls, adjusted for study covariates (see above).
TABLE 1. Demographics of study groups
Baseline
n = 117
Time Point
1 n = 103
Time Point
2 n = 85
Control median age 61 59 59
Biallelic median age 51 52 52.5
Heterozygous median age 60 63 61.5
Signiﬁcance level P = 0.002 P = 0.017 P = 0.031
GBA1 carriers median age 55 56 56
Signiﬁcance level (vs control) P = 0.142 P = 0.505 P = 0.748
Control % male (n) 47 (16) 57 (16) 56 (11)
Biallelic % male (n) 58 (24) 61 (24) 55 (22)
Heterozygous % male (n) 45 (18) 40 (13) 35 (9)
Signiﬁcance level P = 0.537 P = 0.282 P = 0.221
GBA1 % male (n) 51 (42) 50 (37) 49 (31)
Signiﬁcance level (vs. control) P = 0.396 P = 0.404 P = 0.350
Control % family history
PD/dementia (n)
6 (2) 8 (2) 11 (2)
Biallelic % family history
PD/dementia (n)
23 (10) 21 (9) 22 (9)
Heterozygous % family
history PD/dementia (n)
10 (4) 15 (5) 19 (5)
Signiﬁcance level P = 0.062 P = 0.308 P = 0.315
GBA1 % family history
PD/dementia (n)
17 (14) 17 (14) 22 (14)
Signiﬁcance level (vs control) P = 0.084 P = 0.253 P = 0.226
Control % university
educated (n)
68 (24) 63 (17) 74 (14)
Biallelic % university
educated (n)
48 (21) 49 (21) 45 (18)
Heterozygous % university
educated (n)
50 (20) 53 (14) 50 (13)
Signiﬁcance level (vs. control) P = 0.247 P = 0.625 P = 0.100
GBA1 % university educated (n) 0.49 (41) 0.50 (35) 0.48 (31)
Signiﬁcance level (vs. control) P = 0.075 P = 0.199 P = 0.030
Control % smoker (n) 31 (11) 33 (9) 42 (8)
Biallelic % smoker (n) 30 (13) 29 (12) 29 (12)
Heterozygous % smoker (n) 36 (14) 33 (11) 42 (11)
Signiﬁcance level P = 0.851 P = 0.904 P = 0.459
GBA1 % smoker (n) 27 (27) 31 (23) 34 (33)
Signiﬁcance level (vs. control) P = 0.527 P = 0.510 P = 0.361
At baseline, there were 117 participants (35 controls, 39 heterozygous, and
43 biallelic), 103 at time point 1 (28 controls, 33 heterozygous, and
42 biallelic), and 85 at time point 2 (19 controls, 26 heterozygous, and
40 biallelic); 110 participants (32 controls, 36 heterozygous, and 42 biallelic).
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Mann-Whitney U tests were used to compare dependent
variables which were not amenable to stratiﬁcation
(MDS-UPDRS II/III).
Longitudinal Analyses
Repeated-measures logistic regression was used to deter-
mine progression to mild cognitive impairment and micro-
smia, adjusted for study covariates. To carry out this analysis,
it was necessary to dichotomize the data set:
UPSIT: <30 microsmia13
MoCA: <27 mild cognitive impairment14
RBDSQ: >5 RBD15
BDI: >8 mild depression16
A nonparametric trend analysis was undertaken in
the case of signiﬁcant ﬁndings to conﬁrm that this was
a true representation of change in scales. The nonpara-
metric distribution and lack of a clinically validated
threshold meant that we could not perform a longitudi-
nal analyses for MDS-UPDRS II and III.
Trimmed Means
Outliers with disproportionately poor scores in
GBA1 carrier groups drove a non-normal distribution.
Trimmed means were derived by excluding participants
with scores >2 standard deviations (SDs) from the mean
(and recalculating). We did this to provide more repre-
sentative descriptive statistics. Trimmed means did not
form part of any of the statistical analyses.
Severe Mutations
Within the combinedGBA1 group, we generated a logis-
tic regression model assessing the inﬂuence (including all
study covariates) of a number the severe mutations carried
across two alleles (no severemutations = 0, one severemuta-
tions = 1, or two mutations = 2) on all dependent variables,
together with a subset analysis within the heterozygous or
biallelic group alone.
Risk Stratiﬁcation Procedure
To generate an indicator of overall worse/deterioration
of performance, we devised a novel marker of prodromal
PD progression and severity. From the ﬁrst to last time
point, an 0.5-SD fall in the assessment score of each prodro-
mal feature scored 1 point (maximum 4). Another point
was scored for every 0.5 SD that the prodromal feature
score of each participant was below the trimmed mean of
the combinedGBA1 group (maximum4). For each prodro-
mal feature, this produced a combined risk score out of 8. A
summary and example of the stratiﬁcation system are dis-
played in Supporting Information Figure S1.
Symptoms Clustering Analysis
To search for clustering of prodromal PD features in our
GBA1 group, we used our prodromal feature risk scores
(see Risk Stratiﬁcation Procedure section above) to gener-
ate a backward selection ordinal regression model examin-
ing potential associations between the UPSIT risk score
(dependent variable) and other risk scores. The analysis
included all study covariates. The ﬁnal model was repeated
in heterozygous/biallelic carriers/control groups.
Application of MDS Diagnostic Criteria
for Prodromal PD to Cohort
We applied the MDS diagnostic criteria for prodromal
PD to our cohort. This produced a posttest probability
percentage of developing PD for each patient. This was
based upon the following data: age, smoking status, sex,
history of constipation, symptomatic hypotension, erectile
dysfunction, urinary dysfunction, family history of PD,
presence of RBD (as deﬁned by screening questionnaire),
presence of depression, an MDS-UPDRS III score > 3
(excluding action tremor), or the presence of a mild or
severeGBA1mutation. Dopaminergic PET/single-photon
emission computed tomography imaging or data on exces-
sive daytime somnolence were not available.
Serum Alpha-Synuclein Concentration
Serum was collected from 53 members of our longitudi-
nal cohort (28 biallelic, 13 heterozygous, and 12 controls).
This was supplemented by an additional 11 biallelic, 4 het-
erozygous, and 15 control serum samples. Median ages
were: control 64, biallelic 52, and heterozygotes 60. Sixty-
ﬁve percent of the control group, 52% of the biallelic
group, and 61%of the heterozygous groupweremale.
Serum alpha-synuclein (A-SYN) was measured using
the Covance assay (Covance, Dedham,MA). All measure-
ments were performed in duplicate in one batch by board-
certiﬁed laboratory technicians using the same reagents. A
quality-control sample was run at the beginning and end
of each run. Technicians were blinded to clinical/genetic
data. The limit of detection was 1.5 pg/mL.
To compensate for limits of sensitivity, A-SYN concen-
trations were grouped in 10 equal strata (and scored
1–10). Ordinal logistic regression analysis was used to
seek any association between these scores and GBA1 sta-
tus with age and sex as covariates (other demographics
unavailable).We repeated the analysis using the combined
UPSIT + MoCA + BDI risk score. We also carried out a
post-hoc analysis looking for an association between A-
SYN levels and the number of severemutations carried.
Results
Cohort Characteristics
Group demographics are displayed in Table 1. A total
of 117 subjects were included in the cross-sectional analy-
sis (35 controls, 39 heterozygous, and 43 biallelic), One
hundred ten participants (32 controls, 36 heterozygous,
and 42 biallelic) were included in the longitudinal analysis.
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Among the heterozygous group 28 (72%) had no severe
mutations, and 11 (18%) had one severe mutation.
Among the biallelic group, 11 (26%) had no severe muta-
tions, 27 (63%) had one severe mutation, and 5 (11%)
had two severe mutations. A full list of the mutations of
the GBA1-positive participants are shown in Supporting
Information Table S1.
Clinical Assessment Findings
At all three time points for GBA1 mutation carriers,
olfactory disturbance was more prevalent both within the
combined GBA and heterozygous and biallelic groups
(Table 2; Fig. 1). Progression to microsmia was faster
among the combined GBA1 group (odds ratio [OR]: 8.5;
95% conﬁdence interval [CI]: 2.6–28.2; P < 0.05) and
among the heterozygous (OR, 9.9; 95% CI: 2.7–35.9;
P < 0.05) and biallelic (OR, 6.8; 95% CI: 1.6–28.1;
P < 0.05) groups compared to controls (Fig. 1).
Cognitive impairment was worse at all time points
among the combined group of GBA1 carriers. Among
biallelic and heterozygous groups, they were worse at
baseline and at time point 2 for the biallelic group
(Table 2; Fig. 1). Progression tomild cognitive impairment
was worse among the combined GBA1 group (OR, 4.2;
95% CI: 1.1–16.6; P < 0.05), heterozygous (OR, 2.6;
95% CI: 1.6–11.4; P < 0.05), and biallelic group (OR,
8.2; 95%CI: 1.6–41.0; P < 0.05; Fig.1).
Rates of depressive features were worse at time point
2 only, which was mirrored in subset analysis in the het-
erozygous, but not the biallelic, group (Table 2).
Progression to depressive features was not signiﬁcantly
higher among theGBA1 group.
MDS-UPDRS II and III was worse at all time points
in the combined GBA1 group, the heterozygous group,
and the biallelic group at all time points (Table 2;
Fig. 1).
There were no signiﬁcant differences cross-sectionally
or prospectively for RBDSQ scores (Table 2). There was
no association between the number of severe mutations
and any clinical markers at any time point either within
the combined GBA, biallelic, or heterozygous subgroups.
For prospective analyses, we conﬁrmed our ﬁndings repre-
sented a true change in score across theGBA1 group using
a Cuzick trend analysis (olfaction Z = –19.17, P < 0.05;
cognition Z = –3.72, P < 0.05).
Serum A-SYN Is Increased in High-Risk
GBA1 Mutation Carriers
Serum A-SYN was higher in those with higher com-
bined risk scores (UPSIT + MoCA + BDI: OR, 1.4; 95%
CI: 1.0–1.9; P < 0.05). Moreover, A-SYN serum concen-
tration appeared to correlate with the number of
“severe” GBA1 mutations carried (OR, 1.4; 95% CI:
1.05–1.77; P < 0.05).
Illustrative Case GBA1 Biallelic Participant
Who Developed PD
At baseline evaluation in March 2010, a 50-year-old
male with established GD had no clinical features of
PD. By March 2013, when he was 53 years old, he had
FIG. 1. Trimmed means of (A) University of Pennsylvania smell identiﬁcation test (UPSIT), (B) Montreal cognitive assessment (MOCA), and Movement
disorders society uniﬁed Parkinson disease ratings scale (MDS UPDRS) part II (C) and III (D) scores of combined cohort of GBA carriers (dashed line)
and controls (solid line) with exact conﬁdence intervals. At baseline there were 117 participants (35 controls, 39 heterozygous and 43 bi-allelic), 103 at
time-point 1 (28 controls, 33 heterozygous and 42 bi-allelic) and 85 at time-point 2 (19 controls, 26 heterozygous and 40 bi-allelic).
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developed bradykinesia, rigidity, and a unilateral resting
tremor and amarked cognitive deﬁcit, which fulﬁlled diag-
nostic criteria for PD. He was homozygous for R463C, a
severe GD-causing mutation17 which has been described
in several patients with PD and dementia with Lewy bod-
ies.1,3,18 His serum (A-SYN) concentrations were the
highest in the cohort.
Clustering of Prodromal PD Symptoms Among
a Subset of GBA1 Carriers
We hypothesized the existence of a high-risk group
with accelerated progression of a cluster of prodromal
features. We devised a new methodology (see Risk
Stratiﬁcation Procedure section and Supporting Infor-
mation Fig. S1 for details), which took into account the
progression and severity of each prodromal feature. We
then used a backward-selection ordinal logistic regres-
sion model to establish which, if any, of these features
were associated with olfactory deﬁcits, the prodromal
feature found by our analysis to be most affected in
GBA1 cases.
This model revealed that those with olfactory distur-
bance were clustered with impaired cognition (MoCA:
OR, 1.5; 95%CI: 0.0–2.8; P < 0.05) and depression (BDI:
OR, 1.3; 95% CI: 0.6–2.8; P < 0.05). Figure 2 shows that
overlap of (approximately) the worst 10% of participants
with the worst/fastest deteriorating BDI, MoCA, and
UPSIT scores based on our risk stratiﬁcation system
(UPSIT = 3/8: 86th centile and above; MoCA = 3/8: 91th
centile and above; BDI = 4/8: 86th centile and above) com-
pared to the control group (UPSIT 2/8: 89th centile;
MoCA 3/8: 89th centile; BDI 2/8: 87th centile). Subset
analysis showed that this clustering also occurred among
biallelic GBA1 carriers alone, in terms of cognition
(MoCA: OR, 2.95; 95% CI: 1.7–4.5; P = < 0.05), but not
depression. There were no correlations between these risk
scores among the control group (Fig. 2). The combined
risk score was not correlated with the number of severe
disease-causingmutations.
MDS Prodromal PD Criteria
For a probable diagnosis of prodromal PD by the
MDS criteria, an arbitrary cutoff of 80% was applied.
At baseline, none of the cohort met these criteria. The
subject who developed PD did not reach the diagnostic
criteria until the last assessment 4 months after his diag-
nosis was made. His posttest probability scores predia-
gnosis were respectively 11% and 64%. A breakdown
of his assessment scores together with the posttest prob-
abilities derived from the MDS prodromal PD criteria
(and our novel stratiﬁcation scores) are shown in
Supporting Information Table S3.
Discussion
Our results conﬁrm our previous ﬁnding that on lon-
gitudinal analysis, impaired olfaction, cognitive impair-
ment, and the motor prodromal signs and symptoms of
idiopathic PD are more pronounced among GBA1
mutation carriers.11 Currently, clinical trials of a num-
ber neuroprotective compounds targeting the GBA
pathway are ongoing. Within this “at-risk” group,
stratiﬁcation and identiﬁcation of those likely to con-
vert to PD is a priority.
RBD is considered a sensitive prodromal feature of
PD. Previous studies have shown a higher rate of
GBA1 mutations among polysomnographically con-
ﬁrmed RBD cases.20 Our study here did not ﬁnd such
an association at 4 to 5 years, but this probably reﬂects
a limitation of power and, potentially, the sensitivity of
the RBDSQ to detect cases.
FIG. 2. Shows that overlap of participants with the worst/fastest deteriorating BDI, MOCA and UPSIT scores based on our risk stratiﬁcation system
which used as threshold for each test the (approximately) worst 10% of the cohort score for that variable (UPSIT = 3/8: 86th centile and above,
MOCA = 3/8: 91th centile and above, BDI =4/8: 86th centile and above) compared with the control group (UPSIT 2/8: 89th centile, MOCA 3/8: 89th
centile, BDI: 2/8 87th centile). Subset analysis showed that this clustering effect was present within the bi-allelic but not the heterozygous group. At
baseline there were 117 participants (35 controls, 39 heterozygous and 43 bi-allelic), 103 at time-point 1 (28 controls, 33 heterozygous and 42 biallelic)
and 85 at time-point 2 (19 controls, 26 heterozygous and 40 bi-allelic).
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The ﬁnding of raised levels of A-SYN in the serum of
“high-risk” carriers is noteworthy. Both raised and
lowered levels of serum A-SYN have been described in
the context of PD and aging and has not proven a
robust marker of PD progression. Nevertheless, it is
interesting that the 1 subject who developed PD had the
highest levels of A-SYN in the entire cohort, and that
the number of severe GBA1 mutations appeared to cor-
relate with the concentration of serum A-SYN.
It is notable that neither cross-sectionally nor pro-
spectively did any of the prodromal features correlate
with the number of severe mutations carried. Our ﬁnd-
ings suggest that the severity and rate of progression of
prodromal PD symptoms is not inﬂuenced by the num-
ber of severe GBA1 mutations. This may be a symptom
of the logistic regression model we used, which, because
of its reliance on thresholds, may miss subtle differences
in prodromal PD feature severity.
Our novel risk stratiﬁcation system identiﬁed that olfac-
tory disturbance, cognitive impairment, and depression
were clustered together. When this risk stratiﬁcation sys-
tem was applied retrospectively to our subject who devel-
oped PD, his scores were consistently at the 99th centile of
the cohort. In contrast, theMDS prodromal PD diagnostic
criteria failed to make a diagnosis of prodromal PD,
implying that theMDS criteria lack the sensitivity to detect
prodromal PD changes in this population. There is some
evidence to suggest a more variable clinical prodrome of
GBA1 PD, which may also explain the poor performance
of theMDS criteria.21
A recent study in a large cohort of leucine-rich repeat
kinase 2 (LRRK2) to whom the MDS prodromal PD
criteria was applied showed 92% diagnostic speciﬁcity and
80% sensitivity.22 Conversely, in cohort studies in elderly
populations, although speciﬁcity was very high, sensitivity
was estimated at only 14%, 18%, and 54%.23,24 It may be
that these striking differences are a reﬂection of variation
PD incidence.23,24 In RBD25 or G2019S LRRK226 enriched
populations, PD incidence is substantially higher5 and this
is reﬂected in the high likelihood ratios (LRRK2
G2019S = 25, electrophysiologIcally proven RBD = 125)
allocated by theMDS criteria. In contrast,GBA1mutations
score 10 in “severe” and 2 in “mild” mutations. This may
explain the apparent low sensitivity of the criteria among
the general population (and now inGBA1 carriers).
Limitations
The main limitation of the study is the small sample
size, which caused a number of problems. Most nota-
bly, the low penetrance of GBA1 mutations means that
the study is underpowered to track the natural history
of the conversion to PD. It also may be underpowered
to detect other PD prodromal features such as RBD.
Enrichment of the cohort using more sensitive modali-
ties, such as dopaminergic imaging, polysomnography,
or by including only severe mutation carriers, might be
helpful.
The high attrition rate is an issue. While we used
multiple imputation to adjust for dropouts, we cannot
completely rule out the possibility of biases inﬂuencing
dropout, or conversely the character of the dropouts
skewing results. For instance, there was disproportion-
ate dropout of older males who are at a higher risk of
phenoconversion. Accordingly, our data may underesti-
mate the incidence of PD in the cohort.
MDS-UPDRS assessments were carried out by different
assessors at each time point, and this may have introduced
bias; however, we minimized the inﬂuence of this by test-
ing for variation in MDS UPDRS scores and found high
intra-assessor concordance. Biallelic participants were
younger than controls and heterozygotes, as a result of our
recruitment strategy which targeted parents and siblings
of “index” biallelic GD. Given that age was included as a
covariate in all analyses (apart from the MDS-UPDRS II
and III), this is unlikely to be a major confounder. More-
over, given that the PD phenotype is age dependent, a
younger GBA1 cohort would be expected to have milder
prodromal PD features, meaning, if anything, the differ-
ences in prodromal PD features are underestimated.
Conclusion
This study provides further longitudinal evidence of dete-
riorating olfaction, cognition, and motor signs and symp-
toms of parkinsonism among GBA1 carriers without
PD. We found a clustering effect of olfaction, cognitive
impairment, and depression in a subset of participants.
Given the incomplete penetrance of GBA1 in PD, larger
cohorts are required tomap accurately the natural history of
PD conversion among GBA1 carriers (www.rapsodistudy.
com). We suggest that a combination of GBA1 genotyping
and screening of prodromal PD featuresmay aid the identiﬁ-
cation of thosemore likely to develop PD, and, if conﬁrmed,
this would aid targeting of future neuroprotective drugs in
those without PD. Moreover, such a stratiﬁed cohort may
prove a more cost-effective means of adequately powering
neuroprotective trials in this group26.
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